Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones

Leukemia volume 17, pages 634–635 (2003)Cite this article

TO THE EDITOR

We read with interest the letter by Andersen et al1 reporting three cases of chronic myeloid leukemia (CML) with clonal Philadelphia negative (Ph−) hematopoiesis arising after treatment with imatinib mesylate and would like to describe a further interesting patient with some similar features, but a fatal outcome.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brondum-Nielsen K . Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterised by trisomy 8. Leukemia 2002; 16: 1390–1393.

    Article  CAS  Google Scholar 

  2. Socie G, Deeg JC . Malignancies after haematopoietic stem cell transplantation. Many questions, some answers. Blood 1998; 91: 1833–1844.

    PubMed  Google Scholar 

  3. Braziel RM, Launder TM, Druker B, Olson SB, Magenis RE, Mauro MJ et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100: 435–441.

    Article  CAS  Google Scholar 

  4. Meeus P, Demuynck H, Martiat PH, Michaux L, Wouters E, Hagemeijer A . Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib. Leukaemia 2003; 17: 465–467.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Haematology and Cytogenetics, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB25 2ZN, UK

    Y L Chee, M A Vickers, D Stevenson & D J Culligan

  2. Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Royal Infirmary, Glasgow, G31 2ER, UK

    T L Holyoake

Authors
  1. Y L Chee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M A Vickers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Stevenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T L Holyoake
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D J Culligan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chee, Y., Vickers, M., Stevenson, D. et al. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia 17, 634–635 (2003). https://doi.org/10.1038/sj.leu.2402842

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402842

This article is cited by

Search

Advanced search

Quick links